Citations

Showing 10 of 108094 citations.

Female Sex and Gender in Lung/Sleep Health and Disease: Increased Understanding of Basic Biological, Pathophysiological, and Behavioral Mechanisms Leading to Better Health for Female Patients with Lung Disease
Arteaga‐Solis, Emilio, Blenis, John , Bourjeily, Ghada , Clegg, Deborah J. , DeMeo, Dawn L. , Duffy, Jeanne F. , Gaston, B., Heller, Nicola , Jain, Raksha , Lahm, Tim , Lancaster, Lisa , Lee, Joyce , Legato, Marianne J. , McKee, Sherry A. , Mehra, Reena , Morris, Alison , Prakash, Y. S. , Gopal-Srivastava, Rashmi, Laposky, Aaron D., Punturieri, Antonello, Reineck, Lora A., Tigno, Xenia T., Gaston, Benjamin , Prakash, Y S , Han, MeiLan King , Hemnes, Anna R. , Henske, Elizabeth P. , Stämpfli, Martin R. , Clayton, Janine A. , Lee, Joyce S , Mehra, Reena

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 10, 2018 | Volume: 198 | Issue: 7 | Pages: 850-858

10.1164/rccm.201801-0168ws | PMID 29746147 Get It

Abstract Female sex/gender is an undercharacterized variable in studies related to lung development and disease. Notwithstanding, many aspects of lung and sleep biology and pathobiology are impacted by female sex and female reproductive transitions. These may manifest as differential gene expression or peculiar organ development. Some conditions are more prevalent in women, such as asthma and insomnia, or, in the case of lymphangioleiomyomatosis, are seen almost exclusively in women. In other diseases, presentation differs, such as the higher frequency of exacerbations experienced by women with chronic obstructive pulmonary disease or greater cardiac morbidity among women with sleep-disordered breathing. Recent advances in -omics and behavioral science provide an opportunity to specifically address sex-based differences and explore research needs and opportunities that will elucidate biochemical pathways, thus enabling more targeted/personalized therapies. To explore the status of and opportunities for research in this area, the NHLBI, in partnership with the NIH Office of Research on Women’s Health and the Office of Rare Diseases Research, convened a workshop of investigators in Bethesda, Maryland on September 18 and 19, 2017. At the workshop, the participants reviewed the current understanding of the biological, behavioral, and clinical implications of female sex and gender on lung and sleep health and disease, and formulated recommendations that address research gaps, with a view to achieving better health outcomes through more precise management of female patients with nonneoplastic lung disease. This report summarizes those discussions.
Suspected Testosterone-Producing Tumor in a Patient Taking Biotin Supplements
Stieglitz, Heather M., Korpi‐Steiner, Nichole , Katzman, Brooke M. , Mersereau, Jennifer E. , Styner, Maya , Katzman, Brooke, Styner, Maya

Mayo Clinic

Journal of the Endocrine Society | May 10, 2018 | Volume: 2 | Issue: 6 | Pages: 563-569

10.1210/js.2018-00069 | PMID 29942920 Get It

The long noncoding RNA landscape of neuroendocrine prostate cancer and its clinical implications
Ramnarine, Varune Rohan , Alshalalfa, Mohammed , Mo, Fan , Nabavi, Noushin , Erho, Nicholas , Takhar, Mandeep, Shukin, Robert, Brahmbhatt, Sonal, Gawronski, Alexander , Kobelev, Maxim , Nouri, Mannan , Lin, Dong , Tsai, Harrison , Karnes, R., Rubin, Mark A. , Zoubeidi, Amina , Gleave, Martin , Sahinalp, Cenk, Wyatt, Alexander W. , Beltran, Himisha , Wang, Yuzhuo , Collins, Colin C. , Karnes, R Jefferey, Lotan, Tamara Levin , Karnes, R. Jeffrey, Şahinalp, S. Cenk , Volik, Stanislav V. , Davicioni, Elai , Rubin, Mark A

Mayo Clinic

GigaScience | May 10, 2018 | Volume: 7 | Issue: 6 | Pages: No page available

10.1093/gigascience/giy050 | PMID 29757368 Get It

Abstract Background Treatment-induced neuroendocrine prostate cancer (tNEPC) is an aggressive variant of late-stage metastatic castrate-resistant prostate cancer that commonly arises through neuroendocrine transdifferentiation (NEtD). Treatment options are limited, ineffective, and, for most patients, result in death in less than a year. We previously developed a first-in-field patient-derived xenograft (PDX) model of NEtD. Longitudinal deep transcriptome profiling of this model enabled monitoring of dynamic transcriptional changes during NEtD and in the context of androgen deprivation. Long non-coding RNA (lncRNA) are implicated in cancer where they can control gene regulation. Until now, the expression of lncRNAs during NEtD and their clinical associations were unexplored. Results We implemented a next-generation sequence analysis pipeline that can detect transcripts at low expression levels and built a genome-wide catalogue (n = 37,749) of lncRNAs. We applied this pipeline to 927 clinical samples and our high-fidelity NEtD model LTL331 and identified 821 lncRNAs in NEPC. Among these are 122 lncRNAs that robustly distinguish NEPC from prostate adenocarcinoma (AD) patient tumours. The highest expressed lncRNAs within this signature are H19, LINC00617, and SSTR5-AS1. Another 742 are associated with the NEtD process and fall into four distinct patterns of expression (NEtD lncRNA Class I, II, III, and IV) in our PDX model and clinical samples. Each class has significant (z-scores >2) and unique enrichment for transcription factor binding site (TFBS) motifs in their sequences. Enriched TFBS include (1) TP53 and BRN1 in Class I, (2) ELF5, SPIC, and HOXD1 in Class II, (3) SPDEF in Class III, (4) HSF1 and FOXA1 in Class IV, and (5) TWIST1 when merging Class III with IV. Common TFBS in all NEtD lncRNA were also identified and include E2F, REST, PAX5, PAX9, and STAF. Interrogation of the top deregulated candidates (n = 100) in radical prostatectomy adenocarcinoma samples with long-term follow-up (median 18 years) revealed significant clinicopathological associations. Specifically, we identified 25 that are associated with rapid metastasis following androgen deprivation therapy (ADT). Two of these lncRNAs (SSTR5-AS1 and LINC00514) stratified patients undergoing ADT based on patient outcome. Discussion To date, a comprehensive characterization of the dynamic landscape of lncRNAs during the NEtD process has not been performed. A temporal analysis of the PDX-based NEtD model has for the first time provided this dynamic landscape. TFBS analysis identified NEPC-related TF motifs present within the NEtD lncRNA sequences, suggesting functional roles for these lncRNAs in NEPC pathogenesis. Furthermore, select NEtD lncRNAs appear to be associated with metastasis and patients receiving ADT. Treatment-related metastasis is a clinical consequence of NEPC tumours. Top candidate lncRNAs FENDRR, H19, LINC00514, LINC00617, and SSTR5-AS1 identified in this study are implicated in the development of NEPC. We present here for the first time a genome-wide catalogue of NEtD lncRNAs that characterize the transdifferentiation process and a robust NEPC lncRNA patient expression signature. To accomplish this, we carried out the largest integrative study that applied a PDX NEtD model to clinical samples. These NEtD and NEPC lncRNAs are strong candidates for clinical biomarkers and therapeutic targets and warrant further investigation.
Management Reasoning
Cook, David A. , Sherbino, Jonathan , Durning, Steven J.

Mayo Clinic

JAMA | May 10, 2018 | Volume: 319 | Issue: 22 | Pages: 2267

10.1001/jama.2018.4385 | PMID 29800012 Get It

Cannabinoids and gastrointestinal motility: Pharmacology, clinical effects, and potential therapeutics in humans
Camilleri, Michael , Camilleri, M

Mayo Clinic

Neurogastroenterology & Motility | May 10, 2018 | Volume: 30 | Issue: 9 | Pages: No page available

10.1111/nmo.13370 | PMID 29745439 Get It

AbstractBackgroundCannabinoid agents and cannabis are frequently used for relief of diverse gastrointestinal symptoms.PurposeThe objective of this article is to increase the awareness of gastroenterologists to the effects of cannabinoids on gastrointestinal motility, as gastroenterologists are likely to encounter patients who are taking cannabinoids, or those with dysmotility that may be associated with cannabinoid mechanisms. The non‐selective cannabinoid agonist, dronabinol, retards gastric emptying and inhibits colonic tone and phasic pressure activity. In addition to the well‐recognized manifestations of cannabinoid hyperemesis, cannabinoid mechanisms result in human and animal models of gastrointestinal and colonic dysmotility. Decreased enteric FAAH activity is associated with colonic inertia in slow transit constipation and, conversely, the orphan G protein‐coupled receptor, GPR55, is overexpressed in streptozotocin‐induced gastroparesis, suggesting it is involved in inhibition of antral motility. Experimental therapies in gastrointestinal motility and functional disorders are focused predominantly on pain relief mediated through cannabinoid 2 receptors or inhibition of DAGLα to normalize colonic transit. In summary, cannabinoid mechanisms and pharmacology are relevant to the current and future practice of clinical gastroenterology.
Comparison of the QuantiFERON-TB Gold Plus and QuantiFERON-TB Gold In-Tube Interferon Gamma Release Assays in Patients at Risk for Tuberculosis and in Health Care Workers
Theel, Elitza S. , Hilgart, Heather, Breen‐Lyles, Margaret K., McCoy, Kevin , Flury, Rhiannon, Breeher, Laura E. , Sia, Irene G. , Whitaker, Jennifer A. , Clain, Jeremy M., Aksamit, Timothy R. , Escalante, Patricio , Breen-Lyles, Margaret, Clain, Jeremy, Breeher, Laura , Wilson, John , Sia, Irene G

Mayo Clinic

Journal of Clinical Microbiology | May 10, 2018 | Volume: 56 | Issue: 7 | Pages: No page available

10.1128/jcm.00614-18 | PMID 29743310 Get It

ABSTRACT The QuantiFERON-TB Gold Plus (QFT-Plus; Qiagen, Germantown, MD) interferon gamma release assay (IGRA) received FDA clearance in 2017 and will replace the prior version of the assay, the QFT-Gold In-Tube (QFT-GIT). Here, we compared performances of the QFT-Plus assay and the QFT-GIT version in a diverse patient population, including patients undergoing evaluation for or follow-up of latent tuberculosis infection (LTBI; n = 39) or active TB infection ( n = 3), and in health care workers (HCWs; n = 119) at Mayo Clinic (Rochester, MN). Compared to the QFT-GIT, the QFT-Plus assay showed 91.2% (31/34) positive, 98.4% (124/126) negative, and 96.6% (156/161) overall qualitative agreement among the 161 enrolled subjects, with a Cohen's kappa value of 0.91 (excellent interrater agreement). Among the 28 patients diagnosed with LTBI at the time of enrollment, the QFT-GIT and QFT-Plus assays agreed in 24 (85.7%) patients; in all four discordant patients, the positivity of the QFT-GIT or QFT-Plus IGRA was associated with low-level interferon gamma (IFN-γ) reactivity, ranging from 0.36 IU/ml to 0.66 IU/ml. Additionally, we document a high degree of correlation between IFN-γ levels in the QFT-GIT TB antigen tube and each of the two QFT-Plus TB antigen tubes, as well as between the QFT-Plus TB1 and TB2 tubes (Pearson's correlation coefficients [ R ] > 0.95). Overall, we show comparable results between the QFT-GIT and QFT-Plus assays in our study population composed of subjects presenting with a diverse spectrum of TB infections. Our findings suggest that the necessary transition to the QFT-Plus assay will be associated with a minimal difference in assay performance characteristics.
Stress Imaging in Heart Failure
Obokata, Masaru , Borlaug, Barry A. , Borlaug, Barry A , Obokata, Masaru

Mayo Clinic

Circulation: Cardiovascular Imaging | May 10, 2018 | Volume: 11 | Issue: 5 | Pages: No page available

10.1161/circimaging.118.007785 | PMID 29748314 Get It

The Use of Transarterial Approaches in Peripheral Arteriovenous Malformations (AVMs)
Hangge, Patrick T., Albadawi, Hassan , Knuttinen, M. Grace , Alzubaidi, Sadeer , Naidu, Sailendra , Öklü, Rahmi , Chong, Brian W. , Alzubaidi, Sadeer J, Naidu, Sailendra G, Kriegshauser, J. Scott , Oklu, Rahmi , Khurana, Aditya

Mayo Clinic

Journal of Clinical Medicine | May 10, 2018 | Volume: 7 | Issue: 5 | Pages: 109

10.3390/jcm7050109 | PMID 29747435 Get It

Arteriovenous malformations (AVMs) are a subset of congenital vascular malformations (CVMs). They comprise abnormal connections between arterial and venous circulation; treatment approaches are dependent on the angioarchitecture of the AVM, specifically the number and arrangement of the feeder arteries and outflow veins. Various imaging modalities can be used to diagnose and plan treatment. Here we will review the use of transarterial approaches to treat AVMs.
Higher order genomic organization and regulatory compartmentalization for cell cycle control at the G1/S‐phase transition
Ghule, Prachi N. , Seward, David J. , Fritz, Andrew J. , Wijnen, André J. van , Lian, Jane B. , Stein, Janet L. , Stein, Gary S., van Wijnen, Andre J , Boyd, Joseph R.

Mayo Clinic

Journal of Cellular Physiology | May 10, 2018 | Volume: 233 | Issue: 10 | Pages: 6406-6413

10.1002/jcp.26741 | PMID 29744889 Get It

Fidelity of histone gene regulation, and ultimately of histone protein biosynthesis, is obligatory for packaging of newly replicated DNA into chromatin. Control of histone gene expression within the 3‐dimensional context of nuclear organization is reflected by two well documented observations. DNA replication‐dependent histone mRNAs are synthesized at specialized subnuclear domains designated histone locus bodies (HLBs), in response to activation of the growth factor dependent Cyclin E/CDK2/HINFP/NPAT pathway at the G1/S transition in mammalian cells. Complete loss of the histone gene regulatory factors HINFP or NPAT disrupts HLB integrity that is necessary for coordinate control of DNA replication and histone gene transcription. Here we review the molecular histone‐related requirements for G1/S‐phase progression during the cell cycle. Recently developed experimental strategies, now enable us to explore mechanisms involved in dynamic control of histone gene expression in the context of the temporal (cell cycle) and spatial (HLBs) remodeling of the histone gene loci.
Mutated cancer autoantigen implicated cause of paraneoplastic myasthenia gravis
Ζεκερίδου, Αναστασία , Griesmann, Guy E., Lennon, Vanda A. , Zekeridou, Anastasia

Mayo Clinic

Muscle & Nerve | May 9, 2018 | Volume: 58 | Issue: 4 | Pages: 600-604

10.1002/mus.26166 | PMID 29742813 Get It

ABSTRACTIntroduction: Antitumor immune responses are postulated to initiate paraneoplastic neurological disorders when proteins that are normally restricted to neural cells are expressed as oncoproteins. Mutated oncopeptides could bypass self‐tolerant T cells to activate cytotoxic effector T lymphocytes and requisite helper T lymphocytes to stimulate autoantibody production by B lymphocytes. Methods: We investigated muscle‐type nicotinic acetylcholine receptor (AChR) antigen expression at transcriptional and protein levels in a small‐cell lung cancer line (SCLC) established from a patient with AChR‐immunoglobulin G (IgG)‐positive myasthenia gravis. Results: We identified messenger RNA transcripts encoding the 2 AChR α1‐subunit isoforms and 7 alternative‐splicing products, 3 of which yielded premature stop codons. Despite detecting native muscle‐type AChR pentamers in the tumor, we did not identify mutant α1‐peptides. However, we found α1‐subunit‐derived peptides bound to tumor major histocompatibility complex (MHC)1‐protein. In a control SCLC from an antineuronal nuclear autoantibody, type 1 (anti‐Hu)‐IgG‐positive patient, we identified MHC1‐complexed Hu protein‐derived peptides but not AChR peptides. Discussion: Our findings support onconeural protein products as pertinent immunogens initiating paraneoplastic neurological autoimmunity. Muscle Nerve 58: 600–604, 2018